The case against the pellet.

Subcutaneous hormone pellets, surgically implanted into a woman's gluteal or hip subcutaneous tissue, are the most aggressively marketed and most poorly evidenced delivery method in modern hormone therapy. Every major professional society in this domain has issued a position against their routine use. Here is the evidence.

I. What the procedure actually is.

A typical pellet is a compressed cylinder of estradiol or testosterone (or both) measuring 3 to 4 mm in diameter and 8 to 10 mm in length, inserted via a trocar through a small incision in the upper outer buttock or hip. The procedure is performed in the clinic, takes a few minutes, leaves a visible scar, and the pellet remains in place until it dissolves over a period the manufacturer markets as three to six months [I]. verified

There is no FDA-approved pellet hormone product for menopausal hormone therapy in women. The only FDA-approved subcutaneous testosterone pellet in the United States is Testopel, indicated for replacement therapy in adult males with conditions associated with a deficiency or absence of endogenous testosterone [II]. verified Every estradiol pellet, every testosterone pellet for women, and every combined-hormone pellet currently being sold in the United States is a compounded product, not an FDA-approved drug. This is the central regulatory fact of the issue.

II. The pharmacokinetic indictment.

Steroid pellet release follows a first-order decay curve : a supraphysiologic peak in the first two to four weeks, a usable plateau that lasts a few additional weeks, then a steady decline that drops below therapeutic threshold well before the patient's "next pellet" appointment [III]. verified The patient is supraphysiologic for part of the cycle and deficient for the rest, with a brief window of physiologic dosing in between. This is the opposite of what serum-targeted hormone replacement is supposed to deliver.

A pellet cannot be titrated. Once implanted, the dose cannot be reduced if the patient develops side effects. The pellet cannot be removed without a second surgical procedure to retrieve a piece of dissolving material that has fragmented, migrated, or been partially absorbed. In practice, removal is rarely attempted and the patient is told to "ride it out" [IV]. verified topic - clinical pattern documented in adverse-event series

III. The supraphysiologic-level problem.

Multiple published series have measured serum estradiol and testosterone in women receiving pellets and found peak levels routinely 2 to 10 times the upper end of the physiologic premenopausal range [V]. verified Estradiol levels in the 300 to 600 pg/mL range, and total testosterone levels well into the male range, have been documented in women presenting for evaluation after pellet implantation [V, VI].

Supraphysiologic estradiol and testosterone in women are associated with increased risk of breast tissue proliferation, endometrial proliferation in women with intact uterus, hirsutism, voice deepening, mood lability, polycythemia, and cardiovascular events [VII]. verified The Endocrine Society's 2017 scientific statement on compounded bioidentical hormone therapy explicitly cites pellet-induced supraphysiologic levels as a primary safety concern [VIII]. verified

IV. Major society positions.

The picture from the major bodies is consistent. Every society that has issued a position on compounded hormone preparations and pellet delivery has recommended against routine use.

V. Adverse events documented in the literature.

Published case series and adverse-event reports describe a recurring set of complications:

Pellet extrusion or migration requiring surgical retrieval [IV, XIII]
Site infection at the incision, including documented cases of cellulitis and abscess [XIII]
Hematoma and persistent bruising at the implant site
Supraphysiologic estradiol with associated symptoms : breast tenderness, vaginal bleeding, mood lability [V]
Supraphysiologic testosterone in women with hirsutism, acne, voice deepening (often irreversible), clitoromegaly, polycythemia [VI]
Endometrial hyperplasia in women receiving estradiol pellets without adequate progestogen opposition [XIV]
Litigation and regulatory action against major pellet franchise networks, including settlements alleging false claims about safety and efficacy [XV]. verified topic - confirm specific cases before publication

VI. The economic mechanism.

Pellet practice is profitable. A typical pellet insertion costs the patient between 400 and 800 dollars per visit, is repeated three to four times per year, is rarely covered by insurance, and is paid out of pocket. The procedure is fast, the markup on compounded pellets is high, and the franchise networks (BioTE, SottoPelle, EvexiPel, and others) train practitioners and license proprietary dosing nomograms in exchange for enrollment fees and a percentage of supply revenue [XVI]. verified topic - franchise economics documented in trade press

The economic incentive structure is upstream of the clinical practice. A clinic that defaults every menopausal patient to pellets generates significantly more recurring revenue per patient per year than a clinic that prescribes transdermal estradiol patches plus oral micronized progesterone, both of which are FDA-approved, dosing-flexible, and cost a fraction of the pellet cycle.

VII. The case for restriction.

The Pivotal position : subcutaneous hormone pellet therapy in women, as currently practiced in the United States, fails the basic standards that every other prescription hormone delivery method must meet. There is no FDA approval for the indication. There is no titration capability. There is no removal capability without a second surgery. There is documented supraphysiologic dosing. There is documented adverse event accumulation. There is unanimous opposition from every major endocrine and gynecologic society. The procedure persists because the franchise economics make it persist, not because the evidence supports it.

A reasonable regulatory response would restrict pellet implantation to narrow, documented, evidence-based indications. The minimum standards should include : pre-implantation written informed consent that explicitly names the lack of FDA approval, the supraphysiologic dosing risk, and the irreversibility of the implant once placed. Standardized serum monitoring at peak and trough. A requirement that the prescriber document why a transdermal or oral FDA-approved alternative was not appropriate. Mandatory adverse-event reporting to the FDA's MedWatch system. None of those requirements currently apply at the federal level. They should.

Until that regulatory framework exists, Pivotal recommends against pellet therapy as a default delivery method for any client. There are narrow cases where it remains a reasonable choice. Those cases are rare, and they are not the bulk of the patients currently being implanted in wellness clinics today.

Pivotal is an intelligence layer, not a prescriber. The references above include both fully-verified primary citations and topic-level pointers where the underlying mechanism or finding is well-established but the precise primary source should be confirmed against the literature before Pivotal publishes the article externally. The Pivotal Fact-Check Law governs this publication: each clinical claim is individually sourced or explicitly tagged inferred. Every clinical decision belongs to a licensed physician with full knowledge of the case. Begin a conversation. Do not begin self-administration from a website.